Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Camptothecin (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Cao Pharmaceuticals
- 18 Jul 2017 Planned number of patients changed from 60 to 65.
- 18 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 Mar 2018.
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.